ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong>WHY:</strong> Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NKTR" rel="nofollow">NKTR</a>) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important<strong> May 5, 2026 lead plaintiff deadline</strong>.</p> <p align="justify"><strong>SO WHAT:</strong> If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p> <p align="justify"><strong>WHAT TO DO NEXT:</strong> To join the Nektar class action, go to <a href="https://www.globenewswire.com/Tracker?data=ZMKZjcU41yOzqCBaW5uEiVK4FphWI7Ts18wUjyA0jsz0ov6DO0O85Wg8agrnUWNRc6sbwEyMycuwHiYMZBsYUuuyKFCTJksAGzJ_8t0OCjkfGhJgmtWYjT4v01sWn_QHfmp3tct5bwEYx-AYWiJ21UlcZqQF8tsOLGsBmeEO458=" rel="nofollow" target="_blank" rel="nofollow">https://rosenlegal.com/submit-form/?case_id=55599</a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email <a href="https://www.globenewswire.com/Tracker?data=K-ptOxOvSsv-4BZzDaaMsEhYBe2kbaJgYlWw0R3hECJVbdci8mh1nu0xEqALFIiWyzOQI3xQj5pmOh2SXomcSKYgkNNv4S1mL1U4i473cxY=" rel="nofollow" target="_blank" rel="nofollow">[email protected]</a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court <strong>no later than May 5, 2026</strong>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p> <p align="justify"><strong>WHY ROSEN LAW:</strong> We encourage investors to select qualified counsel with a track record of success in leadership roles. ...</p><p><a href=https://www.benzinga.com/pressreleases/26/04/g51670515/rosen-recognized-investor-counsel-encourages-nektar-therapeutics-investors-to-secure-counsel-befor?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel alt=ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR>Full story available on Benzinga.com</a></p>